Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma

被引：0
|
作者：
Takanori Kurogochi
Michitaka Honda
Kotaro Yamashita
Masaru Hayami
Akihiko Okamura
Yu Imamura
Shinji Mine
Masayuki Watanabe
机构：
[1] The Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastroenterological Surgery
[2] Fukushima Medical University,Department of Minimally Invasive Surgical and Medical Oncology
来源：
Surgery Today | 2019年 / 49卷
关键词：
Neoadjuvant chemotherapy; Esophageal cancer; Complications; Daily clinical practice;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：150 / 157
页数：7
相关论文
共 50 条
  • [31] Induction Chemotherapy Followed by Chemoradiotherapy With or Without Consolidation Chemotherapy Versus Chemoradiotherapy Followed by Consolidation Chemotherapy for Esophageal Squamous Cell Carcinoma
    Xiang, Mingyue
    Liu, Bo
    Zhang, Guifang
    Gong, Heyi
    Han, Dali
    Ma, Changsheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [32] Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study
    Zhang, Renquan
    Song, De Sheng
    Liu, Wei
    Yao, Long
    Chen, An Guo
    Ge, Wei
    Hu, Shao Hui
    Chen, Jian
    Huang, Yun Long
    Xun, Jun Rui
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Commentary: Closing the curtain on upfront surgery for esophageal squamous cell carcinoma
    Fairbairn, Kelly
    Molena, Daniela
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 165 (03): : 899 - 900
  • [34] Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis
    Xu, Jinxin
    Yan, Chun
    Li, Zhe
    Cao, Yunpeng
    Duan, Hongbing
    Ke, Sunkui
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (03) : 1597 - 1613
  • [35] Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis
    Jinxin Xu
    Chun Yan
    Zhe Li
    Yunpeng Cao
    Hongbing Duan
    Sunkui Ke
    Annals of Surgical Oncology, 2023, 30 (3) : 1597 - 1613
  • [36] Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy
    Duan, Jingjing
    Deng, Ting
    Ying, Guoguang
    Huang, Dingzhi
    Zhang, Haiyang
    Zhou, Likun
    Bai, Ming
    Li, Hongli
    Yang, Huimin
    Qu, Yanjun
    Wang, Xia
    Ba, Yi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (04) : 336 - 343
  • [37] Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study
    Zheng, Yan
    Li, Yin
    Liu, Xianben
    Zhang, Ruixiang
    Wang, Zongfei
    Sun, Haibo
    Liu, Shilei
    JOURNAL OF CANCER, 2019, 10 (05): : 1097 - 1102
  • [38] Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
    Kadono, Toru
    Yamamoto, Shun
    Hirose, Toshiharu
    Ikeda, Go
    Ohara, Akihiro
    Itoyama, Mai
    Yokoyama, Kazuki
    Honma, Yoshitaka
    Hashimoto, Taiki
    Sekine, Shigeki
    Ishiyama, Koshiro
    Oguma, Junya
    Daiko, Hiroyuki
    Kato, Ken
    ESOPHAGUS, 2023, 20 (01) : 109 - 115
  • [39] Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
    Toru Kadono
    Shun Yamamoto
    Toshiharu Hirose
    Go Ikeda
    Akihiro Ohara
    Mai Itoyama
    Kazuki Yokoyama
    Yoshitaka Honma
    Taiki Hashimoto
    Shigeki Sekine
    Koshiro Ishiyama
    Junya Oguma
    Hiroyuki Daiko
    Ken Kato
    Esophagus, 2023, 20 : 109 - 115
  • [40] Safety and short-term efficacy of preoperative FOLFOX therapy for patients with resectable esophageal squamous cell carcinoma who are not candidates for cisplatin
    Kadono, T.
    Yamamoto, S.
    Ohara, A.
    Itouyama, M.
    Yokoyama, K.
    Honma, Y.
    Ishiyama, K.
    Oguma, J.
    Daiko, H.
    Kato, K.
    ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
12345